<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639743</url>
  </required_header>
  <id_info>
    <org_study_id>P030444</org_study_id>
    <nct_id>NCT00639743</nct_id>
  </id_info>
  <brief_title>PEITHO Pulmonary Embolism Thrombolysis Study</brief_title>
  <acronym>PEITHO</acronym>
  <official_title>Comparison Trial Evaluating Efficacy and Safety of Single i.v. Bolus Tenecteplase Plus Standard Anticoagulation as Compared With Standard Anticoagulation in Normotensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparin is the reference therapy for most patients with pulmonary embolism. Some patients&#xD;
      with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the&#xD;
      right ventricle have a higher mortality risk. It has been suggested that thrombolytic&#xD;
      treatment, a drug that dissolves blood clots more rapidly, may reduce the mortality in those&#xD;
      patients. The studies reported to date were unable to confirm or refute this hypothesis&#xD;
      because the number of patients included in those studies is too low. The aim of the study is&#xD;
      to compare thrombolytic treatment with heparin (which is the reference therapy for pulmonary&#xD;
      embolism) in a large group of patients with sub-massive pulmonary embolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, double-blind, placebo-controlled, international, multicentre,&#xD;
      parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus&#xD;
      tenecteplase plus standard anticoagulation as compared with standard anticoagulation in&#xD;
      normotensive patients with acute pulmonary embolism and with echocardiographic and laboratory&#xD;
      evidence of right ventricular dysfunction.Patients suffering from acute pulmonary embolism&#xD;
      (first symptoms occurring within 15 days) confirmed by lung scanning or a positive spiral&#xD;
      computed tomogram, or a positive pulmonary angiogram, presenting with right ventricular&#xD;
      dysfunction on echocardiography and tested troponin I or T positive will be included in the&#xD;
      study if they have no exclusion criteria.Patients in the investigational group will receive:&#xD;
      Ø Tenecteplase as a single body-weight (known or estimated) adjusted IV bolus administered&#xD;
      over 5 - 10 seconds not later than 30 minutes after randomization, and not later than 2 hours&#xD;
      after the diagnosis of RV dysfunction Weight (kg) Dose in mg Dose in units Dose in ml&lt;60 30&#xD;
      mg 6000 U 6 ml&gt;60 to &lt;70 35 mg 7000 U 7 ml&gt;70 to &lt;80 40 mg 8000 U 8 ml&gt;80 to &lt;90 45 mg 9000 U&#xD;
      9 ml&gt;90 50 mg 10000 U 10 mlØ and: concomitant therapy-Unfractionated heparin at a dose of 80&#xD;
      IUxKg-1 as an intravenous bolus, followed by an infusion of 18 IUxKg-1xh-1, to be&#xD;
      administered immediately after randomization in all patients for at least 48 hours following&#xD;
      randomization. Beyond this period, intravenous UFH may be substituted with subcutaneous&#xD;
      heparin (LMWH) treatment. The bolus will be omitted when heparin was started before&#xD;
      randomisation.Patients in the control group will receive Ø placebo as a single body-weight&#xD;
      (known or estimated) adjusted IV bolus administered over 5 - 10 seconds not later than 30&#xD;
      minutes after randomization, and not later than 2 hours after the diagnosis of RV&#xD;
      dysfunction. Weight (kg) Dose in ml&lt;60 6 ml&gt;60 to &lt;70 7 ml&gt;70 to &lt;80 8 ml&gt;80 to &lt;90 9 ml&gt;90&#xD;
      10 mlØ and concomitant therapy with Unfractionated heparin&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2007</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">July 26, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure &lt; 90 mm Hg for at least 15 min or drop of syst</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic collapse within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed symptomatic pulmonary embolism recurrence within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death within 30 days</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total strokes (intra cranial haemorrhage or ischaemic stroke) within 7 days</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding (other intracranial haemorrhage or ischaemic stroke)</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1005</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tenecteplase (group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo ( group B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo ( group B)</intervention_name>
    <description>placebo ( group B)</description>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenecteplase (group A)</intervention_name>
    <description>tenecteplase (group A)</description>
    <arm_group_label>group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Acute PE (first symptoms occurring 15 days or less before randomisation) confirmed by&#xD;
             lung scan, or a positive spiral computed tomogram, or a positive pulmonary angiogram&#xD;
&#xD;
          -  Right ventricular dysfunction confirmed by echocardiography or spiral computed&#xD;
             tomography of the chest and a positive troponin I or T test&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Haemodynamic collapse at presentation as defined above&#xD;
&#xD;
          -  Known significant bleeding risk&#xD;
&#xD;
          -  Administration of thrombolytic agents within the previous 4 days&#xD;
&#xD;
          -  Vena cava filter insertion or pulmonary thrombectomy within the previous 4 days&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic BP &gt;180 mm Hg and/or diastolic BP &gt;110&#xD;
             mm Hg at randomisation&#xD;
&#xD;
          -  Treatment with an investigational drug under another study protocol in the previous 7&#xD;
             days or greater, according to local requirements&#xD;
&#xD;
          -  Previous enrolment in this study&#xD;
&#xD;
          -  Known hypersensitivity to tenecteplase, alteplase, unfractionated heparin, or to any&#xD;
             of the excipients&#xD;
&#xD;
          -  Pregnancy, lactation or parturition within the previous 30 days. Women of childbearing&#xD;
             age must have a negative pregnancy test or use a medically accepted method of birth&#xD;
             control&#xD;
&#xD;
          -  Known coagulation disorder (including vitamin K antagonists)&#xD;
&#xD;
          -  Any other condition that the investigator feels would place the patient at increased&#xD;
             risk if the investigational therapy is initiated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy MEYER, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux de Paris - Department of pneumology - European Hospital George Pompidou - Paris 15</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stavros Konstantinides, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology and Pulmonolog - Universitaetsmedizin Goettingen - 37099 Goettingen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vienna Medical University</name>
      <address>
        <city>Vienne</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital St. Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universistaetsklinik</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Democritus University of Thrace</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pécs</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Cardiologia, Policlinico S.Orsola-MaBologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Garcia de Orta</name>
      <address>
        <city>Almada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramon y Cajal Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004 Aug 10;110(6):744-9. Epub 2004 Jul 19.</citation>
    <PMID>15262836</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 13, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Heparin</keyword>
  <keyword>Thrombolytic therapy</keyword>
  <keyword>Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

